Tag: Mastocytosis
Blueprint Medicines announces approval of AYVAKYT for treatment of ISM patients in Europe
Blueprint Medicines Corporation today announced the European Commission has approved AYVAKYT® (avapritinib) for the treatment of adult patients with indolent systemic mastocytosis (ISM) with moderate to severe symptoms inadequately controlled on symptomatic treatment. AYVAKYT is the first and only approved therapy for people living with ISM in Europe. Systemic mastocytosis (SM) is a rare hematologic disorder that can […]
